88.7K
Downloads
199
Episodes
Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines. Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.
Episodes
Friday Jun 30, 2023
The CDMO CEO that doesn’t sugarcoat
Friday Jun 30, 2023
Friday Jun 30, 2023
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Marcel Velterop, CEO and Member of the Board at Primopus.
Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Marcel, covering:
- Tips for technical people looking to transition and navigate into a commercial career path
- Why the CDMO business is not for the faint-hearted given the brutal focus on execution and results
- Insights from a lifetime of doing business in India and the key components of a successful tech transfer across multi-national sites
- How oligonucleotides have gone from niche to mainstream, and why an oligos platform presents a major new tool in the healthcare toolbox
Marcel holds a masters degree in chemical engineering from Delft University of Technology and started his career at DSM where he spent 14 years in various roles of growing responsibility. He then joined Dr Reddy’s Laboratories CPS, a CDMO, and subsequently worked for large Indian providers like Sai Life Sciences and Jubilant Biosys. He gained extensive international experience during his 4 years in the US and now over 15 years in Switzerland and aims to work with cultural differences globally and build productive collaborations.
He found purpose in the pharma industry and helping drive innovation as a service provider in the CDMO and CRO industries. During the Covid times, an opportunity presented itself to work for a large India CDMO, who had acquired a GMP API plant just outside Basel, Switzerland. As CEO of Primopus he is building a hybrid business model with complex RSMs and intermediates supplied out of the Swiss site with full backward integration from the large capacity available in India at its parent company.
Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.